Anti-Infectives 2007

Ceftobiprole

• Arias CA, Singh KV, Panesso D, Murray BE. Evaluation of ceftobiprole medocaril against Enterococcus faecalis in a mouse peritonitis model. J Antimicrob Chemother. 2007; 60(3): 594-598.
• Arias CA, Singh KV, Panesso D, and Murray BE. Time-Kill and Synergism Studies of Ceftobiprole against Enterococcus faecalis, Including β-Lactamase-Producing and Vancomycin-Resistant Isolates. Antimicrob Agents Chemother. 2007; 51:2043-7.
• Bush K, Heep M, Macielag MJ, and Noel GJ. Anti-MRSA β-lactams in development, with a focus on ceftobiprole: the first anti-MRSA β-lactam to demonstrate clinical efficacy. Expert Opin Investig Drugs. 2007; 16:419-29.
• Davies TA, Page MG, Shang W, Andrew T, Kania M, and Bush K. Binding of Ceftobiprole and Comparators to the Penicillin-Binding Proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother. 2007; 51(7): 2621-2624. 
• Drew RH. Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections. Pharmacotherapy. 2007; 27:227-49.
• Ednie L, Shapiro S, and Appelbaum PC. Antianaerobe activity of ceftobiprole, a new broad-spectrum cephalosporin. Diagn Microbiol Infect Dis. 2007; 58:133-6.
• Goldstein FW. Combating resistance in a challenging, changing environment. Clin Microbiol Infect. 2007; 13 Suppl 2: 2-6.
• Goldstein F, Perutka J, Cuirolo A et al. Identification and phenotypic characterization of a β-lactam-dependent, methicillin-resistant Staphylococcus aureus (MRSA). Antimicrob Agents Chemother. 2007.
• Jones ME. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect. 2007; 13 Suppl 2:17-24.
• Kosinski MA, Joseph WS. Update on the treatment of diabetic foot infections. Clin Podiatr Med Surg. 2007; 24:383-96. 
• Lodise TP, Jr., Pypstra RMD, Kahn JB MD et al. Probability of Target Attainment for Ceftobiprole as Derived from a Population Pharmacokinetic Analysis of 150 Subjects. Antimicrob Agents Chemother. 2007; 51(7): 2378-2387. 
• Maclayton DO, and Hall RG. Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus. Ann Pharmacother. 2007; 41:235-44.
• Mesaros N, Nordmann P, Plesiat P et al. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect. 2007; 13:560-78.
• Noel GJ. Clinical profile of ceftobiprole, a novel β-lactam antibiotic. Clin Microbiol Infect. 2007; 13 Suppl 2:25-9.:25-9.
• Page MGP. Ceftobiprole - A case study. Expert Opin Drug Discov. 2007; 2(1): 115-129.
• Poulakou G and Giamarellou H. Investigational treatments for postoperative surgical site infections. Expert Opin Investig Drugs. 2007; 16:137-55.
• Queenan AM, Shang W, Kania M, Page MGP, Bush K. Interactions of ceftobiprole with β-lactamases from molecular classes A to D. Antimicrob Agents Chemother. 2007; 51(9): 3089-3095.
• Rossolini GM. Redesigning β-lactams to combat resistance: summary and conclusions. Clin Microbiol Infect. 2007; 13 Suppl 2:30-3.:30-3.
• Rouse MS, Steckelberg JM, Patel R. In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocarditis and bone and joint infection. Diagn Microbiol Infect Dis. 2007; 58:363-65.
• Scheinfeld N. A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus. J Drugs Dermatol. 2007; 6:97-103.
• Yun HC, Ellis MW, Jorgensen JH. Activity of ceftobiprole against community-associated methicillin-resistant Staphylococcus aureus isolates recently recovered from US military trainees. Diagn Microbiol Infect Dis. 2007; 59(4): 463-466.

17th European Congress of Clinical Microbiology and Infectious Diseases ECCMID, April 2007, Munich

• P-710 / Baseline activity of ceftobiprole against methicillin-susceptible and -resistant staphylococcal clinical isolates from Europe collected in 2005-2006. Davies T, Sahm D, Flamm R, Bush K.
• P-779 / Pharmacokinetics of ceftobiprole following single and multiple intravenous infusions administered to healthy subjects. Murthy B, Skee D, Wexler D, Balis D, Chang I, Desai-Kreiger D, Noel G.
• P-780 / Activity of ceftobiprole tested against contemporary European Enterobacteriaceae and Pseudomonas aeruginosa (2005-2006). Fritsche T, Sader H, Strabala P, Jones R.
• P-781 / Activity of ceftobiprole tested against staphylococcal and streptococcal isolates recovered from patients in European medical centres (2005-2006). Fritsche T, Sader H, Strabala P, Jones R.
• P-783 / QT/QTc assessment of ceftobiprole in a single-dose study. Balis D, Strauss R, Murthy B, Tiian H, Noel G.
• P-784 / In vitro activity of ceftobiprole, dalbavancin and tygecycline against methicillin-resistant Staphylococcus aureus strains from hospitalised patients in Belgium. Denis O, Nonhoff C, Deplano A, Hallin M, De Ryck R, Rottiers S, Crevecoeur S, Struelens MJ.
• P-1321 / Regional variation in Panton-Valentine leukocidin positivity among S. aureus isolates in complicated skin and skin structure infections. Strauss R, Amsler K, Jacobs M, Bush K, Noel G.
• P-2024 / Profile of ceftobiprole activity against S. aureus, S. pneumoniae, Enterobacteriaceae, and P. aeruginosa: results of the 2005-2006 Surveillance Program. Aranza MK, Draghi DC, Jones ME, Thornsberry C, Sahm DF.
• P-2025 / Activity of ceftobiprole against US clinical S. pneumoniae isolates that are ceftriaxone non-susceptible. Davies T, Bush K, Appelbaum P.
• P-2026 / Activity of ceftobiprole against Pseudomonas aeruginosa clinical isolates from Europe collected in 2005-2006. Davies T, Sahm D, Flamm R, Bush K.
• P-2027 / Ceftobiprole activity and resistance patterns in staphylococcal isolates from a recent complicated skin and skin structure infection study. Amsler K, Jacobs M, Bajaksouzian S, Windau A, Heep M, Bush K.
• O-120 / Epidemiology of (CA-) MRSA Characteristics of complicated skin and skin structure infections due to staphylococci and the presence of Panton-Valentine leukocidin. Strauss R, Amsler K, Jacobs M, Bush K, Noel G.

Isavuconazole

• Seifert H, Aurbach U, Stefanik D, Cornley O. In Vitro Activity of Isavuconazole and other Antifungal Agents against Candida Bloodstream Isolates. Antimicrob Agents Chemother. 2007 51: 1818-1821.

17th European Congress of Clinical Microbiology and Infectious Diseases ECCMID, April 2007, Munich

• P-987 / Steady-state bioavailability of oral isavuconazole in healthy volunteers. Schmitt-Hoffmann A, Roos B, Heep M.
• P-1675 / QTc measurements during a placebo- and actively controlled multiple dose study of two different dosing regimens of isavuconazole. Heep M, Roos B, Sochor M, Schmitt-Hoffmann A, Van Merle S, Kappers D, Voiriot P.
• P-1676 / Evaluation of isavuconazole (BAL8557/BAL4815) Etest compared to broth microdilution antifungal susceptibility testing against quality control strains and fluconazole susceptible clinical Candida isolates. Heep M, Grover P, Brown NP, Sahm D, Jones ME.
•  P-1951 / Dose response in neutropenic mice with disseminated infection of multiple strains of Aspergillus fumigatus with widely varying MIC and MFC values treated with isavuconazole. Warn PA, Parmar A, Sharp A, Denning DW.
• P-1950 / In vivo efficacy of the triazole BAL8557 against disseminated Candida albicans in mice assessed by survival and tissue burden in temporarily and persistently neutropenic mice treated with 1-7 doses of drug over a dose range of 20-80% of Emax.  Warn PA, Parmar A, Sharp A, Heep M, Spickermann J, Denning DW.
• P-1977 / In vitro activity of isavuconazole (BAL4815/8557) compared with six other antifungal agents against 180 Cryptococcus neoformans meningitis isolates from the Netherlands. Curfs-Breuker I, Illnait-Zaragozi M, Mouton J, Janssen B, Hagen F, Spanjaard L, Boekhout T, Meis J.
• P-1978 / In vitro activity of isavuconazole (BAL4815) compared with seven other antifungal agents against 309 prospectively collected clinical Candida isolates from the Netherlands. Curfs-Breuker I, Mouton J, Debets-Ossenkopp Y, Endtz H, Verweij P, Meis J.